| Literature DB >> 24377397 |
Owain D Thomas1, Anna Gustafsson, Ulf Schött.
Abstract
INTRODUCTION: Routine coagulation tests have a low predictability for perioperative bleeding complications, and spinal hematoma after removal of epidural catheters is very infrequent. Thromboelastometry and point-of-care platelet aggregometry may improve hemostatic monitoring but have not been studied in the context of safety around epidural removal.Entities:
Year: 2013 PMID: 24377397 PMCID: PMC3892080 DOI: 10.1186/1752-1947-7-282
Source DB: PubMed Journal: J Med Case Rep ISSN: 1752-1947
Figure 1Results from assays related mainly to platelet count and function. These results give an overall impression of normo- or hypercoagulability. Shaded areas indicate the normal ranges. Platelet count, ROTEM®-FIBTEM®-maximum clot firmness (taken to be a quantitative measure of blood fibrinogen concentration) and Multiplate® adenosine diphosphate-area under curve (a measure of platelet activity) all correlated significantly to the length of time after surgery (p<0.05, r=0.89, 0.76 and 0.49 respectively). ROTEM®-EXTEM-maximum clot firmness, an overall measure of the extrinsic pathway, neither increased nor decreased with time after operation while ROTEM®-(EXTEM minus FIBTEM®)-maximum clot firmness significantly negatively correlated to time after operation (p<0.05, r=−0.89). The latter measure is often taken to be a measure of platelet function but here its decrease would appear to be due to increasing fibrinogenemia rather than weaning platelet function. *: significant correlation p<0.05. ADP: adenosine diphosphate. AUC: area under curve. MCF: maximum clot firmness. N/S: no significant correlation.
Figure 2Perioperative dynamics of activated partial thromboplastin time and prothrombin time-international normalized ratio. These results give an overall impression of postoperative normo- or hypocoagulability. Shaded areas indicate the manufacturers’ reference ranges. aPTT: activated partial thromboplastin time. PT-INR: prothrombin time-international normalized ratio. Preop: preoperative test results. Postop: test results taken on the day on which epidural catheters were removed. s: seconds. *: significant difference between pre- and postoperative results (p<0.05, Student’s paired t-test).
Summary of assays performed
| ROTEM® using the following reagents: EXTEM, FIBTEM®, INTEM, APTEM, NATEM, HEPTEM®, recording the following results: CT (Clotting time), CFT (Clot formation time), Alpha-Angle (AA), MCF (Maximum Clot Firmness), ML (Maximum Lysis). | 2.7mL citrate tubes for ROTEM® analysis (3.2% citrate, BD Vacutainer® Systems, Plymouth, UK) | ROTEM®, Pentapharm, Munich, Germany | Point-of-care laboratory, Intensive Care Unit | See Table |
| Multiplate® using the following agonists: adenosine diphosphate, collagen, thrombin receptor activator, recording the following results for each agonist: area under curve (AUC), aggregation (AU), velocity (AU/min). | 3.0mL Hirudin tubes. Dynabyte GmbH, Munich, Germany. | Multiplate®, Roche, Basel, Switzerland | See Table | |
| aPTT: activated partial thromboplastin time | 2.7mL citrate tubes (3.2% citrate, BD Vacutainer® Systems, Plymouth, UK) | PTT-Automate, Stago (Asnière sur Seine, France) | Hospital’s usual clinical chemistry laboratory | 28 to 45 seconds at the time of the study |
| PT-INR: prothrombin time-international normalized ratio | Stago prothrombin complex assay, Stago calibrated by Equalis, (Uppsala, Sweden) | ≤1.2 | ||
| Plc: platelet count | 3.0mL K2EDTA tubes (BD Vacutainer® Systems, Plymouth UK) | Sysmex XE 5000 cell counter, Sysmex Corp., (Kobe, Japan). | 165 to 387 million/mL and 145 to 387 million/mL for women and men respectively |
Reference ranges for ROTEM® (Manufacturer’s information) and Multiplate®[6]
| EXTEM | 38–79 | 34–159 | 63–83 | 50–72 |
| APTEM | 38–79 | 34–149 | 63–83 | 50–72 |
| INTEM | 100–240 | 30–110 | 70–83 | 50–72 |
| HEPTEM® | 100–240 | 30–110 | 70–83 | 50–72 |
| NATEM | 300–1000 | 150–700 | 30–70 | 40–65 |
| FIBTEM® | - | - | - | 9–25 |
| (EXTEM-MCF)-(FIBTEM®-MCF) | - | - | - | 41–48 |
| | ||||
| ADPtest | 57–113 | 108–122 | 16–19 | |
| COLtest | 72–125 | 126–140 | 18–21 | |
| TRAPtest | 84–128 | 140–152 | 24–26 |
CT: Clotting time. s: seconds. CFT: Clot formation time. MCF: Maximum clot firmness. AUC: Area under curve. Aggr: aggregation. Vel: velocity. U: units. AU: area units. min: minute.
Routine laboratory results for Case report 1
| Preoperative | 123 | 1.2 | 33 | 266 | 51 | 38 |
| First postoperative day | 103 | 2.5* | 44 | 152 | 43 | 28 |
| At time of epidural catheter removal, fourth postoperative day. | 107 | 1.5* | 33 | 179 | 44 | 29 |
APTT: activated partial thromboplastin time. Hb: hemoglobin. Plc: platelet count. PT-INR: prothrombin time-international normalized ratio. *: outside normal reference range.
Routine laboratory results for Case report 2
| Preoperative | 142 | 1.0 | 25 | 230 | 49 | 36 |
| On tenth postoperative day | 107 | 1.0 | 50* | 149 | 44 | Not measured |
| At time of epidural catheter removal, 11th postoperative day. | 113 | 1.0 | 31 | 178 | 45 | Not measured |
Summary of Case report 2’s routine laboratory studies. APTT: activated partial thromboplastin time. Hb: hemoglobin. Plc: platelet count. PT-INR: prothrombin time-international normalized ratio. *: outside normal reference range.
Routine laboratory results for Case report 3
| Preoperative | 130 | 1.0 | 32 | 201 | 60 | Not measured |
| At time of epidural catheter removal, 2nd postoperative day. | 123 | 1.2 | 47* | 146 | 54 | Not measured |
Summary of Case report 3’s routine laboratory studies. APTT: activated partial thromboplastin time. Hb: hemoglobin. Plc: platelet count. PT-INR: prothrombin time-international normalized ratio. *: outside normal reference range.
Routine laboratory results for Case report 4
| Preoperative | 148 | Not measured | 293 | 61 | 40 | |
| At time of epidural catheter removal, tenth postoperative day. | 96 | 1.0 | 47* | 524 | 71 | 25 |
Summary of Case report 4’s routine laboratory studies. APTT: activated partial thromboplastin time. Hb: hemoglobin. Plc: platelet count. PT-INR: prothrombin time-international normalized ratio. *: outside normal reference range.
Overview of ROTEM parameters
| 1 | NATEM (= ‘classic thromboelastometry’) | Only recalcification agent. | None – coagulation is activated by contact with the surface of the measurement container. | Produces a curve representing ‘whole blood coagulation’. |
| 2 | EXTEM | Tissue factor and phospholipids. | Activates the extrinsic pathway. | CT corresponds to PT. Curve represents clot formation, stability and fibrinolysis resulting from the extrinsic pathway. |
| 3 | INTEM | Ellagic acid and phospholipids. | Activates the intrinsic pathway. | CT corresponds to aPTT. |
| 4 | FIBTEM® | As EXTEM, plus cytochalasin D. | Cytochalasin D inhibits platelets. | Allows qualitative assessment of fibrinogen levels. |
| 5 | APTEM | As EXTEM, plus aprotinin. | Aprotinin inhibits plasmin and therefore fibrinolysis. | Comparing EXTEM and APTEM can rule in or out hyperfibrinolysis. |
| 6 | HEPTEM® | As INTEM, plus heparinase I. | Degrades heparin. | A comparison of HEPTEM® and INTEM indicates how much coagulation is affected by heparin. |
| Gives information about the kinetics of fibrin formation and clot development. Prolongation of CT may be a result of heparin or coagulation factor deficiency. | ||||
| Gives information about the rate of clot formation. It is calculated as the interval between the onset of coagulation, arbitrarily defined as when the amplitude is 2mm, and the curve reaching an amplitude of 20mm. A prolonged CFT but normal MCF indicates a clot polymerization disorder. | ||||
| Indicates the rate at which a solid clot forms. Both CFT and alpha angle are influenced by coagulation factors, platelet count and/or function and fXIII. | ||||
| Shows the maximal strength and stability of the fibrin and platelet clot. A reduced MCF and normal CFT suggest lack of fibrinogen and/or platelets. | ||||
Contents according to manufacturer’s information (Pentapharm, Munich, Germany).